Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown.
Aronne LJ, Horn DB, le Roux CW et al. — The New England journal of medicine
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain.
Nicholls SJ, Pavo I, Bhatt DL et al. — The New England journal of medicine
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown.
Aronne LJ, Sattar N, Horn DB et al. — JAMA
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide an...
Loomba R, Hartman ML, Lawitz EJ et al. — The New England journal of medicine
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, reduces blood glucose and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcome...
Nicholls SJ, Bhatt DL, Buse JB et al. — American heart journal
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described.
Dahl D, Onishi Y, Norwood P et al. — JAMA
Tirzepatide: A Systematic Update
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. GIP and GLP1 are incretin hormones: they a...
Forzano I, Varzideh F, Avvisato R et al. — International journal of molecular sciences
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared ...
Frías JP, Davies MJ, Rosenstock J et al. — The New England journal of medicine
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess efficacy, safety, and tolerability of novel dual glucose-dependent insulinotropic polypept...
Rosenstock J, Wysham C, Frías JP et al. — Lancet (London, England)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clini...
Willard FS, Douros JD, Gabe MB et al. — JCI insight